<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085488</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000370802</org_study_id>
    <secondary_id>DMS-9935</secondary_id>
    <secondary_id>DMS-14862</secondary_id>
    <nct_id>NCT00085488</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>En Vivo Matured Dendritic Cell Therapy in Patients With Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body&#xD;
      build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating patients with stage III or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and the maximum tolerated dose of autologous&#xD;
           dendritic cells pulsed with autologous tumor cell lysate in patients with stage III or&#xD;
           IV melanoma.&#xD;
&#xD;
        -  Determine the safety and tolerability of this therapy in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the immune response, in terms of the type and degree of T-cell proliferation&#xD;
           and delayed-type hypersensitivity responses, in patients treated with this therapy.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, pilot study.&#xD;
&#xD;
      Patients undergo leukapheresis for the collection of peripheral blood mononuclear cells&#xD;
      (PBMC) on days -9, 19, and 47. Autologous dendritic cells (DC) are prepared from autologous&#xD;
      PBMC exposed to sargramostim (GM-CSF), interleukin-4, and tumor necrosis factor alpha and&#xD;
      pulsed with autologous tumor cell lysate. Patients receive autologous tumor cell&#xD;
      lysate-pulsed DC IV over 5-10 minutes on days 0, 28, and 56.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of autologous tumor cell lysate-pulsed DC&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which&#xD;
      33% of all patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at day 84 and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-20 patients will be accrued for this study within 3-20&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Ex Vivo Matured Dendritic Cell Therapy in Patients with Melanoma</measure>
    <time_frame>2005-2006</time_frame>
  </primary_outcome>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma&#xD;
&#xD;
               -  Stage III (lymph node or in-transit metastases) or IV (systemic metastases)&#xD;
                  disease&#xD;
&#xD;
          -  Patients with relapsed disease OR who failed prior immunotherapy or chemotherapy are&#xD;
             eligible (but trial not restricted to relapsed or refractory disease)&#xD;
&#xD;
          -  Tumor tissue available and properly stored for lysate preparation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST ≤ 2 times upper limit of normal (ULN) (3 times ULN for liver metastases)&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 times ULN&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No history of autoimmune disease, including any of the following:&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
          -  No allergy to aminoglycosides or streptomycin&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No significant comorbid illness&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 10 days since prior immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 6 weeks since prior steroid therapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 10 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 10 days since prior surgery&#xD;
&#xD;
          -  Prior diagnostic or palliative surgery allowed provided the patient has fully&#xD;
             recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent immunosuppressive or potentially immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher P. Tretter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>January 30, 2015</last_update_submitted>
  <last_update_submitted_qc>January 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

